VIA Disc NP

What VIA Disc NP does

VIA Disc NP is a product brand of VIVEX Biologics, Inc., a privately held biotechnology company headquartered in Miami, Florida with a regional office in Atlanta, Georgia. The company develops and commercializes the VIA Disc NP nucleus pulposus (NP) allograft, a minimally invasive biologic treatment for lumbar discogenic pain. VIA Disc NP is delivered through a small instrument into the degenerated intervertebral disc via Kambin's safe triangle under fluoroscopy guidance, using a proprietary closed-container preparation system designed to ensure consistent mixing and reduce contamination risk. The product is positioned as the first and only FDA-cleared nucleus pulposus allograft intended to supplement degenerated disc tissue and support natural cushioning function, with in-vitro testing demonstrating water absorption behavior similar to native nucleus pulposus tissue.

The company sells the allograft to hospital outpatient departments (HOPDs) and ambulatory surgery centers (ASCs) through direct field sales, targeting interventional pain physicians and spine surgeons. The procedure is reimbursed under Category III CPT codes 0627T and 0629T, assigned to APC 5115 with a J8 device-intensive payment indicator. VIVEX supports adoption through a Patient Access Program that provides prior authorization assistance, electronic benefits verification, appeal submissions, and real-time case updates via a secure online portal. Clinical evidence includes a 24-month NP Pilot Study showing 64% of participants achieving greater than 50% improvement in back pain and 73% achieving minimum clinically important difference in ODI, as well as an OPP Study in Medicare beneficiaries demonstrating a 60% statistically significant reduction in back pain at 6 months.

VIVEX Biologics traces its origins to the University of Miami Tissue Bank founded in 1970, with 50+ years of allograft development history. The company operates with 51-100 employees, maintains an active LinkedIn presence, and supports its products through peer-reviewed clinical publications and professional medical education at industry conferences. No funding rounds, ownership structure, or revenue figures are publicly disclosed.

Name

VIA Disc NP

Legal name

VIVEX Biologics, Inc.

Website

https://viadiscnp.com

Company type

Private

Founded year

1970

Operating status

Operating

Headcount range

51–100 employees

Short description

VIA Disc NP is a VIVEX Biologics product that develops the first and only nucleus pulposus allograft for minimally invasive treatment of lumbar discogenic pain, sold to hospital outpatient departments and ambulatory surgery centers serving interventional pain physicians and spine surgeons.

Ownership category

akta.pro rank

Product category

Spinal Biologics

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Spine Implants & Motion Preservation (Fusion/Disc/Interspinous) (HLAHAEAC)

Keywords

• Nucleus pulposus allograft
• Spinal biologics
• Minimally invasive spine
• Allograft tissue products
• Disc degeneration treatment

Headquarters

HQ city

Miami

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Allograft Product Sales: VIA Disc NP is sold as an allogeneic tissue transplant to healthcare facilities (HOPDs and ASCs) for use in treating patients with lumbar discogenic pain. The procedure is reimbursed under Category III CPT codes 0627T and 0629T, assigned to APC 5115 with J8 device intensive payment indicator.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

VIA Disc NP is the first and only nucleus pulposus (NP) allograft designed to support the cushioning function of the intervertebral disc and supplement a patient's tissue loss. The product is delivered through a minimally invasive procedure using fluoroscopy imaging to guide a small instrument through Kambin's safe triangle into the nucleus pulposus of the degenerated lumbar intervertebral disc. The product uses a proprietary closed-container preparation system to ensure consistent mixing and reduce contamination risk.

Product overview

VIA Disc NP offers a single unified medical product: the VIA Disc NP nucleus pulposus allograft for treating lumbar discogenic pain. This allograft is supported by supplementary services including a Patient Access Program for prior authorization and reimbursement support. The product is delivered via a minimally invasive procedure using fluoroscopy guidance, targeting patients with tissue loss in their lumbar intervertebral discs.

Differentiator

Problem solved

Functional benefit

Brands

• VIA Disc NP: The first and only nucleus pulposus (NP) allograft intended to support the cushioning function of the intervertebral disc (IVD) and supplement a patient's tissue loss.

Products and services

• VIA Disc NP VIA Disc NP is the first and only nucleus pulposus (NP) allograft intended to support the cushioning function of the intervertebral disc (IVD) and supplement a patient's tissue loss. It is delivered through a minimally invasive procedure using fluoroscopy imaging to guide a small instrument through Kambin's safe triangle into the nucleus pulposus of the intervertebral disc, targeting patients with tissue loss in their lumbar intervertebral discs.

Quantifiable outcome

• 64% of participants achieved >50% improvement in back pain (NRS) at 24 months
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• VIVEX Distribution Network PartnerscoreChannel Partner/ Reseller/ DistributorVIVEX Biologics operates a distribution network for Amnion & Wound Care products. Distribution partners can contact VIVEX through their website to join the network.

Recent moves6 records

Expansion highlights4 records

Direct peers

• Xtant Medical: Xtant Medical develops and markets regenerative medicine products including spinal allografts, bone grafts, and biologics for spine and orthopedic procedures. It is a direct peer because it focuses on biologic implants used in minimally invasive and surgical spine interventions in similar care settings.
• Orthofix Medical: Orthofix Medical provides spine and orthopedic biologics, including bone graft solutions and motion-preserving technologies used in interventional spine care. It is a direct peer because it competes in spine biologics and motion-preservation products sold to hospitals and ambulatory surgery centers.
• RTI Surgical: RTI Surgical is a surgical implant company specializing in biologic allografts and hardware for spine, sports medicine, and surgical applications. It is a direct peer because it sells allograft-based spine products through hospitals and ambulatory centers using a comparable biologic implant commercial model.
• LifeNet Health: LifeNet Health is a non-profit allograft tissue bank that develops and distributes biologic grafts for spine, orthopedic, and wound care applications. It is a direct peer because it manufactures and supplies allograft tissue products to hospitals and ASCs in overlapping clinical channels.

Emerging players

• Centinel Spine: Centinel Spine specializes in motion-preserving spinal technologies, including total disc replacement systems and biologic adjuncts for cervical and lumbar disc disease. It is an emerging player because it directly addresses discogenic pathology with motion-preservation principles similar to VIA Disc NP's value proposition.
• Alphatec Holdings: Alphatec is a spine-focused medical device company developing procedural solutions and implants for degenerative and deformity spine surgery. It is an emerging player that competes in the same surgeon and ASC channels for interventional spine volumes, though its portfolio is broader in hardware than biologics.
• Camber Spine: Camber Spine is a privately held spine device company focused on procedurally integrated implants and biologics for degenerative spine conditions. It is an emerging player with overlapping motion-preservation and biologic offerings aimed at the same interventional spine call points.

Broad incumbents

• Medtronic (Spine & Biologics): Medtronic's Spine & Biologics business offers spinal fusion hardware, motion-preservation devices (including artificial discs), and biologic solutions sold to spine surgeons and hospitals. It is a broad incumbent that competes for the same interventional spine procedure volumes and could launch adjacent biologic offerings.
• Globus Medical (formerly NuVasive): Globus Medical, which merged with NuVasive, is one of the largest spine technology companies offering implants, biologics, and enabling technologies for degenerative and deformity spine surgery. It is a broad incumbent because it competes across the spine implant category with deep hospital relationships and a far larger portfolio than VIA Disc NP.
• Stryker (Spine division): Stryker is a major medical device company with a spine division offering cervical and thoracolumbar implants, biologics, and surgical tools used in interventional and surgical spine procedures. It is a broad incumbent with overlapping customer relationships and channel reach into HOPDs and ASCs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/viadiscnp
• Facebookfacebook.com/viadiscnp

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VIA Disc NP